Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

Findings showed 64.7% of icotrokinra-treated patients achieved IGA scores 0/1 and 49.6% achieved PASI 90 compared with 8.3% and 4.4% of those on placebo, respectively. Topline results were ...

It wasn’t until two years after her symptoms began that she finally found a dermatologist who identified her “itchy spots” as evidence of plaque psoriasis, a chronic autoimmune disorder that ...

Plaque psoriasis is the most common type of psoriasis. Plaques are pink/red, raised, thick, inflamed skin patches covered by silvery-white scales. They typically have well-defined edges and may itch.

Guttate psoriasis may represent the initial stage of chronic plaque-type psoriasis. On resolution, post-inflammatory hypo or hyperpigmentation may result. There is no scarring. Patients should be ...

Johnson & Johnson (J&J) has reported positive topline outcomes from its Phase III ICONIC-LEAD trial of oral icotrokinra (JNJ-2113) for treating moderate to severe plaque psoriasis in patients aged ...

for the treatment of children 6 years and older with moderate-to-severe plaque psoriasis (PsO) and children 5 years of age and older with active juvenile psoriatic arthritis (jPsA).a The PsO ...